{"transactions":[{"id":730827,"issuer":{"id":1008,"kind":"organization","name":"RECURSION PHARMACEUTICALS, INC.","symbol":"RXRX"},"owners":[{"id":36440,"kind":"person","name":"Bumpus Namandje","position":1,"cik":"0002060594","reported_name":"Bumpus Namandje","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2026-06-22T20:32:02.000Z","date":"2026-06-18","kind":"sale","planned":true,"acquired":false,"shares":3963,"price":3.18,"value":12602.34,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This transaction is pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 3, 2026."}],"balance_after":127632,"source":{"system":"sec-edgar","filing":"0001601830-26-000082","document":"wk-form4_1782160319.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2060594/000160183026000082/wk-form4_1782160319.xml","form_type":"4"}},{"id":730826,"issuer":{"id":1008,"kind":"organization","name":"RECURSION PHARMACEUTICALS, INC.","symbol":"RXRX"},"owners":[{"id":36440,"kind":"person","name":"Bumpus Namandje","position":1,"cik":"0002060594","reported_name":"Bumpus Namandje","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2026-06-22T20:32:02.000Z","date":"2026-06-17","kind":"grant","planned":true,"acquired":true,"shares":88424,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents a grant of restricted stock units automatically granted pursuant to the Issuer's Outside Director Compensation Policy. The restricted stock units will vest on the earlier of June 17,2027 or the day prior to the Issuer's 2027 Annual Meeting of Stockholders, subject to the Reporting Person's continued service to the Issuer."}],"balance_after":131595,"source":{"system":"sec-edgar","filing":"0001601830-26-000082","document":"wk-form4_1782160319.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2060594/000160183026000082/wk-form4_1782160319.xml","form_type":"4"}},{"id":749920,"issuer":{"id":1008,"kind":"organization","name":"RECURSION PHARMACEUTICALS, INC.","symbol":"RXRX"},"owners":[{"id":36440,"kind":"person","name":"Bumpus Namandje","position":1,"cik":"0002060594","reported_name":"Bumpus Namandje","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2026-06-04T21:04:57.000Z","date":"2026-06-03","kind":"sale","planned":true,"acquired":false,"shares":4386,"price":3.54,"value":15526.44,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction is pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 3, 2026."}],"balance_after":43171,"source":{"system":"sec-edgar","filing":"0002060594-26-000003","document":"wk-form4_1780607095.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2060594/000206059426000003/wk-form4_1780607095.xml","form_type":"4"}},{"id":1104134,"issuer":{"id":1008,"kind":"organization","name":"RECURSION PHARMACEUTICALS, INC.","symbol":"RXRX"},"owners":[{"id":36440,"kind":"person","name":"Bumpus Namandje","position":1,"cik":"0002060594","reported_name":"Bumpus Namandje","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-23T21:23:02.000Z","date":"2025-06-18","kind":"grant","planned":false,"acquired":true,"shares":22016,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to this option will vest and become exercisable on the earlier of June 18, 2026 or the date of the Issuer's 2026 Annual Meeting of Stockholders, subject to the Reporting Person's continued service to the Issuer."}],"balance_after":22016,"derivative":{"exercise_price":5.11,"expiration_date":"2035-06-18","underlying":"Class A Common Stock","underlying_shares":22016},"source":{"system":"sec-edgar","filing":"0001601830-25-000108","document":"wk-form4_1750713775.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2060594/000160183025000108/wk-form4_1750713775.xml","form_type":"4"}},{"id":1104133,"issuer":{"id":1008,"kind":"organization","name":"RECURSION PHARMACEUTICALS, INC.","symbol":"RXRX"},"owners":[{"id":36440,"kind":"person","name":"Bumpus Namandje","position":1,"cik":"0002060594","reported_name":"Bumpus Namandje","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2025-06-23T21:23:02.000Z","date":"2025-06-18","kind":"grant","planned":false,"acquired":true,"shares":11008,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents a grant of restricted stock units automatically granted pursuant to the Issuer's Outside Director Compensation Policy. The restricted stock units will vest on the earlier of June 18, 2026 or the day prior to the Issuer's 2026 Annual Meeting of Stockholders, subject to the Reporting Person's continued service to the Issuer."}],"balance_after":47557,"source":{"system":"sec-edgar","filing":"0001601830-25-000108","document":"wk-form4_1750713775.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2060594/000160183025000108/wk-form4_1750713775.xml","form_type":"4"}},{"id":1197431,"issuer":{"id":1008,"kind":"organization","name":"RECURSION PHARMACEUTICALS, INC.","symbol":"RXRX"},"owners":[{"id":36440,"kind":"person","name":"Bumpus Namandje","position":1,"cik":"0002060594","reported_name":"Bumpus Namandje","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-03-19T20:27:28.000Z","date":"2025-03-17","kind":"grant","planned":false,"acquired":true,"shares":73099,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Represents a grant of options automatically granted pursuant to Recursion's Outside Director Compensation Policy. The shares subject to this option will vest and become exercisable as to 1/3rd of the shares subject to the award on the first three anniversaries of March 17, 2025, subject to the Reporting Person continuing to be a service provider through the applicable vesting dates."}],"balance_after":73099,"derivative":{"exercise_price":6.84,"expiration_date":"2035-03-17","underlying":"Class A Common Stock","underlying_shares":73099},"source":{"system":"sec-edgar","filing":"0001601830-25-000048","document":"wk-form4_1742416041.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2060594/000160183025000048/wk-form4_1742416041.xml","form_type":"4"}},{"id":1197430,"issuer":{"id":1008,"kind":"organization","name":"RECURSION PHARMACEUTICALS, INC.","symbol":"RXRX"},"owners":[{"id":36440,"kind":"person","name":"Bumpus Namandje","position":1,"cik":"0002060594","reported_name":"Bumpus Namandje","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2025-03-19T20:27:28.000Z","date":"2025-03-17","kind":"grant","planned":false,"acquired":true,"shares":36549,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents a grant of restricted stock units automatically granted pursuant to Recursion's Outside Director Compensation Policy. The restricted stock units will vest as to 1/3rd of the shares subject to the award on the first three anniversaries of March 17, 2025, subject to the Reporting Person continuing to be a service provider through the applicable vesting dates."}],"balance_after":36549,"source":{"system":"sec-edgar","filing":"0001601830-25-000048","document":"wk-form4_1742416041.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2060594/000160183025000048/wk-form4_1742416041.xml","form_type":"4"}}]}